Analyst firms · UBS · JNJ
UBS JNJ price target and rating history
Johnson & Johnson (JNJ) · Health Care
UBS rates Johnson & Johnson (JNJ) Buy with a $320 price target, as of its latest action on Sep 2, 2026. It has published 3 rating actions on JNJ since March 2023, including 1 upgrade and 0 downgrades. Across 5 firms with a JNJ price target in the last 12 months, the median target is $262. UBS's $320 is 22% above that.
- Current rating
- Buy
- Price target
- $320
- Median target, all firms
- $262
- Actions on JNJ
- 3
UBS price target on JNJ
Every UBS rating on JNJ
- Sep 2, 2026
- Dec 1, 2023
- Mar 29, 2023
How other firms rate JNJ
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Erste Group | Hold | Oct 21, 2026 | |
| UBS | Buy | $320 | Sep 2, 2026 |
| Leerink Partners | Outperform | $265 | May 13, 2026 |
| TD Cowen | Buy | $250 | Apr 8, 2026 |
| Morgan Stanley | Overweight | $262 | Jan 28, 2026 |
| Scotiabank | Sector Outperform | $230 | Nov 13, 2025 |
Questions about UBS and JNJ
- What is UBS's price target for JNJ?
- UBS's latest stated price target for Johnson & Johnson (JNJ) is $320, from its action on Sep 2, 2026.
- What is UBS's rating on JNJ?
- UBS rates JNJ Buy, a bullish rating, as of Sep 2, 2026.
- When did UBS last change its view on JNJ?
- On Sep 2, 2026, UBS resumes coverage at Buy, price target $320.
- How does UBS's JNJ target compare with other analysts?
- Across 5 firms with a JNJ price target in the last 12 months, the median target is $262. UBS's $320 is 22% above that.
More JNJ rating histories
All UBS ratingsJNJ news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.